Analyst Optimism | Price targets range from $22 to $36, reflecting confidence in MM120's potential. However, current trading remains in the $8-$9 range as of mid-2024. |
Market Potential | Analysts project MM120 could reach $2.29 billion in revenue by 2031, tapping into a multi-billion-dollar market for anxiety treatment. |
Clinical Success | Phase 2b trials reveal MM120's significant anxiety reduction, rapid onset, and sustained effects for up to 12 weeks, outperforming current therapies. |
Breakthrough Anxiety Treatment | MindMed's MM120, an LSD-based compound, shows promise in treating generalized anxiety disorder with a single dose, potentially revolutionizing mental health care. |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Metrics to compare | MNMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNMDPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.3x | −0.8x | −0.6x | |
PEG Ratio | −1.61 | 0.00 | 0.00 | |
Price / Book | 2.2x | 0.8x | 2.6x | |
Price / LTM Sales | - | 2.7x | 3.2x | |
Upside (Analyst Target) | 286.8% | 61.2% | 43.9% | |
Fair Value Upside | Unlock | 15.8% | 7.8% | Unlock |